We develop innovative bispecific antibody therapies, specifically targeting unmet needs in solid tumors.

Shelley Force Aldred, Ph.D., is a co-founder, investor, and CEO of Rondo Therapeutics. Prior to starting Rondo, Shelley was a member of Teneobio’s founding team where she led preclinical development for the company’s CD3 T-cell engager platform which ultimately generated $1.5B in up-front payments through partnerships and an acquisition by Amgen.  Early in her career, Shelley developed a passion for starting companies when she co-founded SwitchGear Genomics and later sold it to Active Motif. Shelley earned a Ph.D. in Genetics from Stanford where she continues to be involved as an advisor for Stanford’s SPARK translational medicine program and as a member of the Board of Governors for the Stanford Medicine Alumni Association.

Nathan is a co-founder, investor, and board member of Rondo Therapeutics and currently serves as President and CSO. Prior to starting Rondo, Nathan was Chief Technology Officer at Teneobio where he played a key role in starting the company and led the team that was responsible for lead discovery, lead optimization, and development of the T-cell engager platform that was acquired in 2021. Prior to Teneobio, Nathan was a co-founder and CEO of SwitchGear Genomics, venture-backed functional genomics platform company that was acquired in 2013. Earlier in his career, Nathan served as the Technical Director of the Stanford ENCODE project and received his Ph.D from Stanford University. Nathan also serves on the Board of Governors for the Stanford Medicine Alumni Association. Nathan has published over 30 peer-reviewed papers and is an inventor on over 15 patents.

Katherine is Chief Development Officer at Rondo Therapeutics and brings over a decade of experience advancing antibody-based therapeutics to the clinic. Previously, she was the Vice President of Discovery at Amgen and Teneobio, where she led successful Oncology Research teams, advancing clinical candidates that resulted in 4 IND approvals in less than 6 years. She joined Teneobio when the company started lab operations in 2015, playing a key role in both building and managing a high-throughput antibody discovery platform. Prior to her work at Teneobio, she was a research scientist at Active Motif and SwitchGear Genomics where she focused her efforts on developing a functional genomics platform for small molecule screening. Katherine also serves on the Board of Directors for The Antibody Society. Katherine holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She has presented in numerous national and international conferences, has multiple peer-reviewed publications and is an inventor on more than 15 patents.

Thomas serves as Chief Medical Officer at Rondo Therapeutics and brings over 25 years of oncology clinical research and development experience.  Prior to starting at Rondo, Thomas was VP of Clinical Development at IGM Biosciences, where he led several T cell engager programs in heme and solid tumor indications.  Prior to IGM, Thomas was VP of Clinical Development and Medical Affairs at Adaptive Biotechnologies. Earlier in his career, he led several ADC programs in heme indications, including clinical lead for a successful sBLA for Adcetris in peripheral T cell lymphomas. Thomas did his clinical and research fellowship at Fred Hutchinson Cancer Center and Seattle Children's Hospital.

Lynnae Jackson brings over 30 years of clinical research experience to her role as Vice President of Clinical Operations at Rondo Therapeutics, with nearly two decades dedicated to oncology drug development. Her expertise spans early-stage clinical trials through Phase 2proof-of-concept trials, with a focus on advancing novel therapeutics from IND submission to first-in-human studies. Before joining Rondo, Lynnae held executive roles at Iambic Therapeutics and Pionyr Immunotherapeutics, where she led operational teams in the development of oncology assets. Earlier in her career, she held key leadership positions at Amgen—where she contributed to the successful sBLA for Aranesp®—and at Astellas, where she was instrumental in developing several ADC programs, including the approval of Padcev® for metastatic bladder cancer. Lynnae is an active member of the University of Washington PHARBE Advisory Board and has presented at numerous national and international conferences. She is also a published author with over 20 scientific publications. She holds a B.S. from Pepperdine University and a B.S. in Biology from San Francisco State University.

Meghana is VP of business development, leading outreach and partnering efforts for Rondo Therapeutics. She is an experienced business development professional, with a science-centric approach to transact biopharma partnerships. Meghana joined Rondo from Johnson & Johnson Innovation, where she served as Director of Early Innovation Partnering for Oncology. There she led end-to-end deal flow, including sourcing, due diligence, and negotiating research collaboration and licensing deals in immuno-oncology and hematology. Prior to Johnson & Johnson, Meghana was a management consultant for Syneos Health, building strategic plans for Medical Affairs oncology teams at mid and large pharma. Meghana holds a PhD from Vanderbilt University in Cancer Biology.

Starlynn leads the pre-clinical biology group at Rondo Therapeutics, an IO-focused biopharmaceutical company developing innovative bispecific therapeutic antibodies for treating solid tumors. She has worked in discovery and preclinical development in the fields of oncology and immunology at several biotechnology start-up companies, including Frontier Medicines and Caribou Biosciences. As a founding member of the pre-clinical biology team at Teneobio, a highly successful multi-specific therapeutic antibody company, she contributed to several bispecific antibody programs currently in clinical trials. Starlynn completed her PhD in the lab of Charles Craik at UCSF, where she studied novel viral and fungal host-pathogen interactions.

Udaya is Director of translational biology at Rondo Therapeutics. Prior to Rondo, Udaya was a Principal Scientist at Amgen following Amgen’s acquisition of Teneobio in 2021. At both Amgen and Teneobio, Udaya has played a key role in multiple heme-oncology programs taking T cell engager molecules from lead optimization through first-in-human studies, including three programs that are in active clinical trials. Prior to Teneobio, Udaya was a post-doc at MedImmune/Astrazeneca working on mechanisms of oncolytic virotherapy. Udaya received her PhD in microbiology and molecular genetics from Emory University and identified novel signaling pathways driving the pathogenesis of an oncogenic viral protein. 

Brian Avanzino is Director of discovery research at Rondo Therapeutics where he leads teams focused on the discovery and development of novel multispecific antibodies for the treatment of solid tumors. Previously, he was at Amgen and Teneobio where he led and advanced several T cell engager programs through various stages of research and development including target validation, lead discovery, lead optimization, and preclinical studies. He also managed and contributed to the optimization of a high-throughput sequence-based antibody discovery platform. Brian holds a PhD in Biochemistry and Molecular Biology from the University of California, Davis, where he studied the regulation of viral protein synthesis.

Tatjana leads the Protein Sciences team at Rondo Therapeutics and brings over a decade of experience in protein biochemistry. Prior to joining Rondo, she worked at several biotech companies including Alector, Synthekine, and Caribou Biosciences focusing on therapeutics discovery and development in neurodegeneration, cytokine immunotherapies, and CRISPR-Cas engineering. Her work on anti-inflammatory cytokines contributed to a successful collaboration with a large pharmaceutical company. Earlier in her career, she transitioned to biotech with a postdoc at Genentech in the Early Discovery Biochemistry Department identifying novel interactions for proteins in chromatin biology. Tatjana received her PhD from the Freie University of Berlin (Germany) and completed her graduate research in the lab of Michael Botchan at the University of California, Berkeley where she studied the fundamental mechanisms of eukaryotic DNA replication. She has multiple peer-reviewed publications and patents.